TECX TECTONIC THERAPEUTIC INC.

Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference

Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025.

Bank of America Securities Health Care Conference

Date:Thursday, May 15th, 2025
Time:9:20am PDT
Format:Corporate Presentation
Presenter:Alise Reicin, MD, President and Chief Executive Officer
Webcast:

The Tectonic management team will host one-on-one meetings at the conference. Interested investors should contact their Bank of America Securities representative to schedule meetings.

The live webcast can also be accessed under “” on the Investors section of the Tectonic website at . Once the conference has concluded, a replay of the webcast will be available on the Company’s website for approximately 90 days.

About Tectonic

is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit and follow us on .



Investors:
Dan Ferry
LifeSci Advisors
 
(617) 430-7576

Media:
Kathryn Morris
The Yates Network
 
(914) 204-6412
EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TECTONIC THERAPEUTIC INC.

 PRESS RELEASE

Tectonic Therapeutic to Participate in March Investor Conferences

Tectonic Therapeutic to Participate in March Investor Conferences WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026. TD Cowen 46th Annual Health Care Conference  Date:March 4, 2026Time:11:10 AM ESTLocation:Boston, MAFormat:Fireside ChatPresenters:Al...

 PRESS RELEASE

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Finan...

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potentia...

 PRESS RELEASE

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Indep...

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) --  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more ...

 PRESS RELEASE

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX210...

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET. ...

 PRESS RELEASE

Tectonic Therapeutic to Participate in December Investor Conferences

Tectonic Therapeutic to Participate in December Investor Conferences WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Presenters:Webcast:December 2, 20253:30 PM ESTNew Yo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch